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AML patients in CR1 who underwent Allo-SCT with RIC
regimen (Flu-Bu2-hATG) at UMass since 2010.
Results: 18 patients (12 males; 6 females) with a median age
of 67.5 (range 24-83) years were identiﬁed. Twelve (66%) had
prior MDS or poor prognostic cytogenetics. Induction
chemotherapy consisted of High dose Ara-C (HIDAC)/
Anthracycline (n¼17) and Decitabine (n¼1). Five patients
required reinduction to achieve a CR. Fourteen (78%)
received post CR therapy: HIDAC (n¼5), HIDAC/Hypo-
methylating agent (n¼3) and Hypomethylating agent alone
(n¼6). Seven (39%) patients had inadequate recovery of
counts (CRi). Median time from diagnosis to SCT was 130.5
(range 33 -384) days. Median Hematopoietic (H) SCT co-
morbidity index (CI) was 2.5 range (1- 9). SCT donors were
sibling (n¼2) and unrelated (n¼16). Seventeen (94%) pa-
tients were 8/8 HLA match and one (6%) was 7/8 HLA match.
Stem cell source was peripheral blood (n¼17) and G-CSF
primed marrow (n¼1). RIC dosing was Bu (3.2 mg/kg day x
2), Flu (30mg/m2 x 6) and hATG (20mg/kg x 3). Graft versus
Host Disease (GvHD) prophylaxis was calcineurin inhibitor/
mycophenolate-mofetil (MMF) (n¼16) and Sirolimus/MMF
(n¼2).
Median CD34 cells infusedwere 5 x 10e6/kg range (2.5-6).
All patients engrafted with a median time to neutrophil
engraftment of 15 days (range 10-22) and a median time to
platelet engraftment of 15 days (range 0-21). Non relapse
mortality at 100 days was 5.9%. Cumulative incidence of
grade 2-4 acute GvHD was 39%. For patients alive beyond 6
months the cumulative incidence of chronic gvhd was 64%.
Kaplan Meier estimate of 2 year overall (OS) and progression
free survival (PFS) was 80.5 % (95% CI 50.6-93.3%) and 69.9 %
(95% CI 36.7-88.0%) The median follow-up for the survivors
was 509 (59-1288) days. No patient with HSC-CI < 5 died
while all 3 patients with HSCT-CI > 6 expired (p < .001).
Presence of chronic gvhd was associated with a better PFS
(100% versus 32.1%) (p< .02) and a tendency for better OS
(100% versus 57.1%) (p¼ .06) indicating a preservation of
graft versus leukemia effect with this regimen.
Conclusion: Flu-Bu2-hATG RIC regimen has low early mor-
tality and improved PFS and OS for AML patients undergoing
Allo-SCT in CR1. The regimen should be evaluated in a pro-
spective clinical trial.223
Synergistic Cytotoxic Effect of the PARP Inhibitor ABT888
and Busulfan in Acute Leukemia Cell Lines
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Chicago, ILThe alkylator Busulfan (Bu) is used in conditioning regimens
for acute leukemia prior to allogeneic stem cell transplant.
Multiple DNA repair mechanisms including mismatch repair
and base excision repair have been implicated in resistance
to Bu. The enzyme PARP is central to base excision repair. We
hypothesized that treatment of acute leukemia cell lines
with both ABT888 (Veliparib), an inhibitor of PARP 1 and 2,
and Buwould lead to synergistic cell kill and that this effect is
maximal in mismatch repair deﬁcient cells.
Two mismatch repair proﬁcient cell lines (K562 and HL60)
and 2 mismatch repair deﬁcient cell lines (NB4 and REH)
were treated with ABT888 alone, Bu alone or a combination
of both. In single drug experiments, doses of drug treatment
ranged from 0-400mcg/ml. In combination experiments a
ﬁxed dose of ABT888 of 1.25mcg/ml was utilized with Bu
doses varying from 0-200mcg/ml. This dose of ABT888 was
chosen as it approximated to patient blood levels in clinical
trials. After 24 hours of treatment, cells were washed and
resuspended in fresh medium. Proliferation of cells was
measured by standard 3H-thymidine uptake assay at 48
hours. Sigmoidal dose response curves and GI50 values were
then calculated. In addition, cells were tested for apoptosis
by ﬂow cytometry using activated caspase 3 and annexin/ PI
staining at 24 and 48 hours after treatment.
All 4 cell lines were found to be resistant to single agent
ABT888. Despite mismatch repair deﬁciency in REH cells,
therapeutic doses of ABT888 did not cause signiﬁcant de-
creases in proliferation. The effect of ABT888 was, as ex-
pected, much less evident in the mismatch repair proﬁcient
K562 cells. These cells were also relatively resistant to single
agent Bu in vitro. The combination of Bu and ABT888 was
synergistic in all cell lines with GI50 (micromoles/ml) for Bu
decreasing from 67.8 to 45.7 in K562, from 23.3 to 8.0 in
HL60, from 46.6 to 36.1 in NB4 and from 34.4 to 17.0 in REH
cells. The Combination Index was <1 in all cell lines indi-
cating synergy. Dose Reduction Index, indicating the factor
by which the dose of Bu can be decreased to achieve the
same treatment effect size, ranged from 1.45 to 3.1. The
synergistic effect was greatest in the mismatch repair deﬁ-
cient cell line REH (Combination Index 0.53, Dose Reduction
Index 3.1). As expected the synergistic effect observed did
not correlate with increased apoptotic death of leukemic
cells.
To our knowledge, this is the ﬁrst study to show synergy of a
clinically available PARP inhibitor with Bu. We believe this
data warrants further study with the potential clinical
application of increasing the anti-leukemic effect of stem cell
transplantation conditioned with Bu containing preparative
regimens.224
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Introduction: Overall survival (OS) after a standard allogeneic
hematopoietic cell transplantation (alloHCT) for refractory
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shown to reduce AML relapse for patients in CR1. Cyclophos-
phamide in the conditioning is suspected of contributing to
signiﬁcant toxicity. Preliminary work with high doses of TBI
(16Gy), without cyclophosphamide, followed by an HLA
matched related or unrelated donor (MRD or MUD)-alloHCT
has resulted in long-term remissions in 2 out of 4 patients.
Based on these encouraging results we initiated and report on
the preliminary results of a phase 2 study of single agent
extended dose TBI (ED-TBI) (18Gy).
Methods: Patients (18-60 years old) with rAML and an HLA
MRD or MUD received an alloHCT after ED-TBI, 2.25Gy BID
(days -4 to -1) x 8 fractions (total 18Gy). Donor cells were
infused on day 0. Tacrolimus (day -3) and mycophenolate
mofetil (MMF) (day 1) were used for graft vs. host disease
(GVHD) prophylaxis. Toxicity was measured using the CTCAE
v.4 and the LENT-SOMA scales. The primary end point was
treatment related mortality (TRM). Secondary endpoints
included: engraftment, morbidity/mortality at 30, 100 and
>180 days, incidence of GVHD, relapse rate and one year
progression-free (PFS) and OS.
Results: Patients: Five patients have been enrolled. One pa-
tient had rAML following two induction attempts. Another
patient had rAML (secondary) after one induction attempt
and three had relapsed (<6months) rAML. All had persistent
leukemia at the start of ED-TBI, with 4 out of 5 having > 50%
blast cells in the marrow.
Toxicity: <30 days, 2 patients had grade 3 mucositis. Two
patients required parenteral feeding. One patient experienced
reversible veno-occlusive disease. All patients developed
diarrhea. Two patients suffered from grade 3 dehydration,
requiring prolonged intravenous hydration (days 37-107).
Engraftment: Neutrophil engraftment occurred between
days 15-25 and the patients were discharged from the hos-
pital between days 19-30.
GVHD: Immunosuppression was completely tapered at
day 101 in 1 patient. One patient continues to taper off at day
217, due to persistent chronic GVHD (cGVHD) and 3 did not
complete tapering before relapse. Acute GVHD occurred in 1
patient <day 30, treated with prednisone. cGVHD occurred
in all patients >day 100, involving the GI tract (n¼2) and
liver (n¼2). One patient has persistent cGVHD beyond 4
months involving the mouth and lungs.
Response: Of the 4 patients who had circulating blast
cells, all were cleared by day 1. Two patients are in contin-
uous CR on days 217 and 338. Three patients have relapsed at
days 96, 110 and 139 and died on days 106, 145 and 257,
respectively.
Conclusion: rAML is controlled by ED-TBI followed by an
alloHCT. The toxicity of ED-TBI is acceptable and comparable
to other alloHCT conditioning regimens. Safety and efﬁcacy
are continuing to be assessed with a goal to recruit 20
patients.225
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The nucleoside analogs clofarabine (Clo) and ﬂudarabine
(Flu), together with the DNA alkylating agent busulfan (Bu),
are commonly used as part of the pre-transplant conditioningregimen in allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). The multikinase inhibitor sorafenib
(Sor) has clinical activity in FLT3-ITD-positive acute myeloid
leukemia (AML). We previously reported that a combination
of [Bu+Clo+Flu] has a synergistic cytotoxicity in AML cells.We
now hypothesized that Sor, if combined with [Bu+Clo+Flu],
will further enhance this cytotoxicity. We exposed the FLT3-
ITD-mutated AML cell line MV4-11 to low concentrations of
Bu (1 mg/ml), Clo (10 nM), Flu (2.5 mM) and Sor (1 nM) alone or
in various combinations. Exposure of the cells to Bu, Clo, Flu
or Sor alone, or to two-drug combinations [Bu+Clo], [Bu+Flu]
and [Clo+Flu], did not signiﬁcantly affect cell proliferation or
apoptosis relative to control cells. The combination of
[Bu+Clo+Flu] resulted in 20% inhibition of cell proliferation
and demonstrated 10% increase in apoptosis. Addition of Sor
to the [Bu+Clo+Flu] mixture further enhanced the inhibition
of proliferation by 60%, and increased apoptosis to 50%, sug-
gesting synergistic cytotoxicity. Biochemical analyses suggest
that this cytotoxicity may be attributed to (1) activated DNA-
damage response (2) histone 3modiﬁcations, (3) inhibition of
different kinases, and (4) activation of the intrinsic apoptosis
pathway. The phosphorylation of kinases, including FLT3,
MEK and AKT, was signiﬁcantly inhibited when cells were
exposed to [Bu+Clo+Flu+Sor]. FLT3-ITD-activated STAT5 and
its target gene Pim 2, a serine threonine kinase, were both
down-regulated when cells were exposed to Sor alone,
[Bu+Clo+Flu] and [Bu+Clo+Flu+Sor]. The level of the pro-
apoptotic protein PUMA increased, while the pro-survival
proteins MCL-1 and Bcl-xL were down-regulated when cells
were exposed to the four-drug combination. The levels of
phosphorylated and total P53 increased in the mitochondria
when cells were exposed to [Bu+Clo+Flu] or [Bu+Clo+-
Flu+Sor]. The changes in the levels of these proteins involved
in mitochondrial control of apoptosis may consequently
cause mitochondrial outer membrane permeabilization
(MOMP). The mitochondrial membrane potential (MMP), a
marker of MOMP, decreased by 20% and 60% when cells were
exposed to [Bu+Clo+Flu] and [Bu+Clo+Flu+Sor], respectively.
This drug-mediated decrease in MMP may have caused
leakage of cytochrome c, SMAC/DIABLO and AIF from the
mitochondria to the cytoplasm and/or nucleus, leading to
caspase activation, nuclear fragmentation and cell death.
These results provide amechanistic basis for investigating the
addition of sorafenib in future clinical trials of (double)
nucleoside analog-busulfan combinations in pre-transplant
conditioning therapy for patients undergoing allo-HSCT for
FLT3-ITD positive AML.LYMPHOMA/MULTIPLE MYELOMA226
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